Neuralink Receives Canadian Approval for Brain Chip Clinical Trial
Key Insights
Neuralink has been approved to begin its first clinical trial in Canada, focusing on a brain chip designed to enable paralyzed individuals to control digital devices with their thoughts.
The Canadian study will assess the safety and initial functionality of Neuralink's implant in individuals with quadriplegia, allowing them to control external devices using their thoughts.
University Health Network in Toronto has been selected to perform the neurosurgical procedure for the Canadian clinical trial, marking a significant step in Neuralink's expansion.

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.